---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-332748"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2026-08-04T20:04:05+00:00"
generated_at: "2026-08-04T20:05:08.820028+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis Q2 revenue up 30% to $22.4M; clinical test volume surges 199% YoY

## Summary
- Clinical test volume of 10,384, up 199% YoY and 33% sequentially; clinical revenue $2.6M (+442% YoY).
- Total revenue $22.4M (+30% YoY); pharma testing & other revenue $16.8M (+51%); VA MVP revenue $3.0M (-9%).
- Cash and investments $212.7M; secured Medicare coverage for NeXT Personal IO monitoring and neoadjuvant breast cancer.
- VICTORI study: NeXT Personal detected 100% of relapses; TRACERx data highlights sub-10 ppm sensitivity in lung cancer.
- Due to pending merger with Tempus AI, company will no longer provide financial guidance or hold earnings call.

## SEC filing metadata
- accession: 0001193125-26-332748
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2026-08-04T20:04:05+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312526332748/0001193125-26-332748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312526332748/psnl-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-332748
- JSON: https://secwatch.observer/filing/0001193125-26-332748.json
- Plain text: https://secwatch.observer/filing/0001193125-26-332748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.